Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Rink, M; Adam, M; Hansen, J; Chun, FK; Ahyai, SA; Remzi, M; Schlomm, T; Engel, O; Heuer, R; Eichelberg, C; Fisch, M; Dahlem, R; Shariat, SF.
[Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].
Urologe A. 2012; 51(9):1228-39
Doi: 10.1007/s00120-012-2911-9
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ahyai Sascha
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Upper urinary tract urothelial carcinoma (UTUC) is an uncommon but potentially lethal disease. Accurate risk stratification remains a challenge owing to the difficulty of clinical staging. Identification of risk factors may lead to individualized treatment and patient counselling and holds the potential to improve outcome. A non-systematic PubMed/Medline literature research was performed to identify and summarize clinical and pathological risk factors and urine-based markers which are associated with clinical outcome. Although knowledge of potential prognostic factors has improved over the last 5 years the overall evidence on UTUC risk factors remains limited and prospective, randomized trials are still missing. Radical nephroureterectomy is currently standard treatment for high-grade and muscle invasive UTUC. Several clinical and pathological factors (e.g. stage, grade, age, hydronephrosis, lymphovascular invasion, tumor necrosis and architecture, delay between diagnosis and surgery) were identified to be associated with outcome. Urinary cytology and fluorescence in-situ hybridization are the most commonly used urinary markers. Prospective randomized controlled trials are urgently needed to identify new risk factors and assess the efficacy. The incorporation of such prognosticators into multivariable prediction models may help to guide decision-making with regard to type of treatment, performance of lymphadenectomy and consideration of neoadjuvant or adjuvant systemic therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Carcinoma, Transitional Cell - diagnosis, mortality, therapy
- Evidence-Based Medicine - administration & dosage
- Humans - administration & dosage
- Prevalence - administration & dosage
- Prognosis - administration & dosage
- Risk Assessment - administration & dosage
- Survival Analysis - administration & dosage
- Survival Rate - administration & dosage
- Treatment Outcome - administration & dosage
- Urologic Neoplasms - diagnosis, mortality, therapy
- Urothelium - pathology
- Find related publications in this database (Keywords)
- Urothelial carcinoma
- Urinary tract, upper
- Prognosis
- Survival
- Risk factors